Mark M. Awad, MD, PhD, discusses the characterization of patients with non–small cell lung cancer who have MET exon 14 skipping alterations and potential acquired resistance mechanisms.
Mark M. Awad, MD, PhD, clinical director of the Thoracic Oncology Treatment Center at Dana-Farber Cancer Institute and assistant professor of Medicine at Harvard Medical School, discusses the characterization of patients with non–small cell lung cancer (NSCLC) who have MET exon 14 (METex14) skipping alterations (SA) and potential acquired resistance mechanisms.
In this study, which was done in collaboration with Foundation Medicine, over 60,000 patients with NSCLC were investigated and 1387 (2.3), had METex14 mutations. Awad says this is an important and emerging subset of lung cancer to identify, especially now since there is an FDA-approved targeted therapy called capmatinib (Trabrecta) for patients with METex14 SA.
Since this is a relatively new target in the lung cancer setting, it is more important to identify the characteristics of these cancers to see what other mutations may be present within the genome as much as possible, according to Awad. The trial also looked to answer whether there are other factors that may regulate response or resistance to either immunotherapy or to targeted therapy.
<< View more of Targeted Oncology's coverage from the 2020 ASCO Virtual Annual Meeting
Cretostimogene Grenadenorepvec Shows High CR Rate in BCG-Unresponsive NMIBC
July 17th 2024Mark D. Tyson, II, MD, MPH, discussed treatment with cretostimogene grenadenorepvec in high-risk Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer with carcinoma in situ and data from the BOND-003 trial.
Read More
Examining Breast Cancer Recurrence Detection Methods in a Community Oncology Setting
July 12th 2024In an interview with Targeted Oncology, Ali Duffens, MD, discussed findings from a study which investigated detecting breast cancer recurrence among women treated at Kaiser Permanente Northern California.
Read More